Evidence map›Paper›PMID 36358956›Full record

ArticleBiomolecules2022

Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study.

Manuel Galiñanes, Kelly Casós, Arnau Blasco-Lucas, Eduard Permanyer, Rafael Máñez, Thierry Le Tourneau, Jordi Barquinero, Simo Schwartz, Tomaso Bottio Jean Christian Roussel, Imen Fellah-Hebia and 10 more

Open access · goldAbstract readClinical Study
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Essential Hypertension and Oxidative Stress: Novel Future Perspectives.International journal of molecular sciences · 2022
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 4 countries.

Manuel GaliñanesReparative Therapy of the Heart, Vall d'Hebron Research Institute (VHIR), Passeig Vall d'Hebron, 119; Autonomous University of Barcelona (UAB), 08035 Barcelona, Spain.ORCID 0000-0002-0888-976X
Kelly CasósReparative Therapy of the Heart, Vall d'Hebron Research Institute (VHIR), Passeig Vall d'Hebron, 119; Autonomous University of Barcelona (UAB), 08035 Barcelona, Spain.
Arnau Blasco-LucasReparative Therapy of the Heart, Vall d'Hebron Research Institute (VHIR), Passeig Vall d'Hebron, 119; Autonomous University of Barcelona (UAB), 08035 Barcelona, Spain.
Eduard PermanyerReparative Therapy of the Heart, Vall d'Hebron Research Institute (VHIR), Passeig Vall d'Hebron, 119; Autonomous University of Barcelona (UAB), 08035 Barcelona, Spain.
Rafael MáñezInfectious Diseases and Transplantation Division, Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital-ICS, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Thierry Le TourneauCHU Nantes, Institut du Thorax, Université de Nantes, CIC 1413, F-44000 Nantes, France.
Jordi BarquineroGene and Cell Therapy, VHIR, UAB, Barcelona, Spain.
Simo SchwartzGroup of Drug Delivery and Targeting, Vall d'Hebron Research Institute (VHIR), Clinical Biochemistry Department, Vall d`Hebron Hospital Barcelona Campus, 08035 Barcelona, Spain.ORCID 0000-0001-8297-7971
Tomaso Bottio Jean Christian RousselDepartment of Cardio Thorac Vascular Sciences and Public Health, Padua University Hospital, 35128 Padua, Italy.ORCID 0000-0001-7299-2983
Imen Fellah-HebiaCHU Nantes, Institut du Thorax, Université de Nantes, CIC 1413, F-44000 Nantes, France.
Thomas SénageCHU Nantes, Institut du Thorax, Université de Nantes, CIC 1413, F-44000 Nantes, France.
Arturo EvangelistaDepartment of Cardiology, Vall d'Hebron Research Institut (VHIR), Hospital Vall d´Hebron, 08035 Barcelona, Spain.
Luigi P BadanoDepartment of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.
Alejandro Ruiz-MajoralDepartment of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Cesare GalliAvantea and Fondazione Avantea Onlus, 26100 Cremona, Italy.
Vered Padler-KaravaniDepartment of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.
Jean-Paul SoulillouInstitut de Transplantation-Urologie-Néphrologie, INSERM Unité Mixte de Recherche 1064, Centre Hospitalier Universitaire de Nantes, 44093 Nantes, France.
Xavier VidalDepartment of Clinical Pharmacology, HUGH-ICS, 08001 Barcelona, Spain.
Emanuele CozziTransplant Immunology Unit, Department of Transfusion Medicine, Padua University Hospital, 35128 Padua, Italy.
Cristina CostaInfectious Diseases and Transplantation Division, Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital-ICS, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Universitat Autònoma de Barcelona · ESBellvitge University Hospital · ESCentre Hospitalier Universitaire de Nantes · FRUniversity of Padua · ITVall d'Hebron Institut de Recerca · ESAvantea · ITCentre National de la Recherche Scientifique · FRInserm · FRInstitut du Thorax · FRIRCCS Istituto Auxologico Italiano · ITTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cause of structural valve deterioration (SVD) is unclear. Therefore, we investigated oxidative stress markers in sera from patients with bioprosthetic heart valves (BHVs) and their association with SVD. Blood samples were taken from SVD (Phase A) and BHV patients during the first 24 (Phase B1) and >48 months (Phase B2) after BHV implantation to assess total antioxidant capacity (TAC), malondialdehyde (MDA), and nitrotyrosine (NT). The results show that MDA levels increased significantly 1 month after surgery in all groups but were higher at 6 months only in incipient SVD patients. NT levels increased gradually for the first 24 months after implantation in the BHV group. Patients with transcatheter aortic valve implantation (TAVI) showed even higher levels of stress markers. After >48 months, MDA and NT continued to increase in BHV patients with a further elevation after 60-72 months; however, these levels were significantly lower in the incipient and established SVD groups. In conclusion, oxidative stress may play a significant role in SVD, increasing early after BHV implantation, especially in TAVI cases, and also after 48 months' follow-up, but decreasing when SVD develops. Oxidative stress potentially represents a target of therapeutic intervention and a biomarker of BHV dysfunction.

Indexed as

Aortic Valve StenosisHeart Valve ProsthesisAortic ValveHumansOxidative StressProsthesis DesignProsthesis FailureTreatment Outcomeaortic valvebiological heart valveslipid peroxidationoxidative stressprotein nitrationstructural valve deteriorationtranscatheter aortic valve implantation

Identifiers

PMID36358956
PMCPMC9687638
OpenAlexW4308121351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.